Valuation GlaxoSmithKline Pharmaceuticals Limited NSE India S.E.
Stocks
GLAXO
INE159A01016
Pharmaceuticals
|
Market Closed -
NSE India S.E.
20:11:04 14/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 2,688.80 INR | +0.79% |
|
+4.24% | +8.70% |
| 08-03 | GSK India first-quarter profit rises on steady vaccine demand | RE |
| 08-03 | GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: GlaxoSmithKline Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 281,714 | 224,319 | 329,173 | 487,432 | 386,822 | 455,550 | - |
| Change | - | -20.37% | 46.74% | 48.08% | -20.64% | 17.77% | - |
| Enterprise Value (EV) | 256,351 | 207,663 | 329,173 | 487,432 | 386,822 | 455,550 | 455,550 |
| Change | - | -18.99% | 58.51% | 48.08% | -20.64% | 17.77% | 0% |
| P/E | 16.6x | 36.7x | 55.8x | 52.5x | 37.3x | 39.2x | 34.1x |
| PBR | 10.6x | 12.9x | 18.5x | 25x | 17.1x | 17.2x | 14.5x |
| PEG | - | -0.6x | -16.49x | 0.9x | 3.2x | 3.3x | 2.3x |
| Capitalization / Revenue | 8.59x | 6.9x | 9.53x | 13x | 10.1x | 10.7x | 9.66x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 10.7x | 9.66x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 30.8x | 26.8x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 31.2x | 26.8x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 37.9x | 34.6x |
| FCF Yield | 2.75% | 1.96% | 1.67% | 2.6% | 2.19% | 2.64% | 2.89% |
| Dividend per Share 2 | 30 | 32 | 32 | 42 | 57 | 29.5 | 29.5 |
| Rate of return | 1.8% | 2.42% | 1.65% | 1.46% | 2.5% | 1.1% | 1.1% |
| EPS 2 | 100 | 36.05 | 34.83 | 54.76 | 61.15 | 68.52 | 78.88 |
| Distribution rate | 30% | 88.8% | 91.9% | 76.7% | 93.2% | 43% | 37.4% |
| Net sales 1 | 32,780 | 32,517 | 34,537 | 37,492 | 38,217 | 42,528 | 47,167 |
| EBITDA 1 | 8,273 | 8,043 | 9,087 | 11,774 | 13,092 | 14,794 | 17,020 |
| EBIT 1 | 7,592 | 7,385 | 8,390 | 11,106 | 12,428 | 14,621 | 17,016 |
| Net income 1 | 16,947 | 6,107 | 5,900 | 9,276 | 10,360 | 11,611 | 13,364 |
| Net Debt | -25,363 | -16,656 | - | - | - | - | - |
| Reference price 2 | 1,662.95 | 1,324.15 | 1,943.10 | 2,877.30 | 2,283.40 | 2,689.10 | 2,689.10 |
| Nbr of stocks (in thousands) | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | - |
| Announcement Date | 16/5/22 | 17/5/23 | 17/5/24 | 13/5/25 | 13/5/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.32x | 12.47x | 25.45x | 0.57% | 1,078B | |
| 29.15x | - | - | 2.05% | 632B | |
| 32.02x | 7.45x | 15.48x | 2.73% | 443B | |
| 20.19x | 4.79x | 11.87x | 2.76% | 356B | |
| 21.62x | 5.6x | 13.97x | 2.87% | 289B | |
| 20.24x | 4.18x | 11.87x | 2.1% | 245B | |
| 26.43x | 6.88x | 12.21x | 2.41% | 226B | |
| 13.48x | 4.84x | 10.07x | 3.78% | 204B | |
| -42.9x | 6.13x | 34.58x | 2.39% | 171B | |
| Average | 17.17x | 6.54x | 16.94x | 2.41% | 404.85B | |
| Weighted average by Cap. | 24.53x | 8.19x | 18.66x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- GLAXO Stock
- Valuation GlaxoSmithKline Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
